In recent years, the development of tumor immunotherapy has provided new therapeutic ideas for malignant hematological diseases such as MDS, etc. TIM-3, as an important immune checkpoint molecule, is often highly expressed in myeloid and lymphoid tumor cells on the one hand, which promotes malignant proliferation and immune escape, and on the other hand, it can also be expressed on a wide range of immune cells (e.g., T cells, NK cells, DC cells, macrophages, etc.), which affects immune effects and inflammatory microenvironment. Here, HAVCR2 is linked to neoplasm.